Randomized trial comparing dose reduction and growth factor supplementation for management of hematological side effects in HIV/hepatitis C virus patients receiving pegylated-interferon and ribavirin

Journal of Acquired Immune Deficiency Syndromes

Volumn 58, Issue 3, 2011, Pages 261-268

  Talal, Andrew H ^a   Liu, Ruei Chi ^b   Zeremski, Marija ^a   Dimova, Rositsa ^a   Dove, Lorna ^c   Pearce, Daniel ^d   Hassanein, Tarek ^e   Doonquah, Leleka ^f   Aboulafia, David ^g   Rodriguez, Jorge ^h   Bonilla, Hector ⁱ   Galpin, Jeffrey ^j   Aberg, Judy A ^k   Johnston, Barbara ^l   Glesby, Marshall J ^a   Jacobson, Ira M ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b Department of Biostatistics ^*  (United States)

^c Och Spine at New York Presbyterian Hospitals   (United States)

^d WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

^e SCTI Liver Center Research Foundation   (United States)

^f Family Medical Counseling Services Inc   (United States)

^g VIRGINIA MASON MEDICAL CENTER   (United States)

^h Orange Coast Medical Group   (United States)

ⁱ SUMMA HEALTH SYSTEM   (United States)

^j Shared Medical Research Foundation   (United States)

^k NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l ST VINCENT S HOSPITAL   (United States)

more..

Author keywords

anemia; granulocyte colony stimulating factor; hepatitis C virus HIV coinfection; neutropenia; recombinant human erythropoietin

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; HEMOGLOBIN; PEGINTERFERON ALPHA2B; RECOMBINANT ERYTHROPOIETIN; RIBAVIRIN;

ADULT; AGED; ANEMIA; ARTICLE; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MULTICENTER STUDY; NEUTROPENIA; NEUTROPHIL COUNT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; AGED; ANEMIA; ANTIVIRAL AGENTS; ERYTHROPOIETIN; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTERFERON-ALPHA; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN;

EID: 80054886875     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3182324af9     Document Type: Article

References (39)

1. Brau N. Treatment of chronic hepatitis C in human immunodeficiency virus/hepatitis C virus-coinfected patients in the era of pegylated interferon and ribavirin. Semin Liver Dis. 2005;25:33-51. (Pubitemid 40322349)
2. Puoti M, Manno D, Nasta P, et al. The burden of HIV and hepatitis C virus coinfection. Curr Opin HIV AIDS. 2007;2:460-465. (Pubitemid 351339525)
3. Carrat F, Bani-Sadr F, Pol S, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIVinfected patients: a randomized controlled trial. JAMA. 2004;292: 2839-2848. (Pubitemid 39628231)
4. Torriani FJ, Rodriguez-TorresM, Rockstroh JK, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med. 2004;351:438-450. (Pubitemid 38988593)
5. Chung RT, Andersen J, Volberding P, et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med. 2004;351:451-459. (Pubitemid 38988594)
6. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358: 958-965. (Pubitemid 32913521)
7. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347: 975-982.
8. Laguno M, Murillas J, Blanco JL, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS. 2004;18:F27-F36. (Pubitemid 39179626)
9. Mauss S. Treatment of viral hepatitis in HIV-coinfected patients-adverse events and their management. J Hepatol. 2006;44:S114-S118. (Pubitemid 43053886)
10. Moreno L, Quereda C, Moreno A, et al. Pegylated interferon alpha2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients. AIDS. 2004;18:67-73. (Pubitemid 38402319)
11. Crespo M, Sauleda S, Esteban JI, et al. Peginterferon alpha-2b plus ribavirin vs interferon alpha-2b plus ribavirin for chronic hepatitis C in HIV-coinfected patients. J Viral Hepat. 2007;14:228-238. (Pubitemid 46452410)
12. Dienstag JL, McHutchison JG. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology. 2006;130:231-264; quiz 214-237. (Pubitemid 43049856)
13. McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology. 2002;123:1061-1069.
14. Talal AH, Weisz K, Hau T, et al. A preliminary study of erythropoietin for anemia associated with ribavirin and interferon-alpha. Am J Gastroenterol. 2001;96:2802-2804. (Pubitemid 32889234)
15. Afdhal NH, Dieterich DT, Pockros PJ, et al. Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology. 2004;126:1302-1311. (Pubitemid 38552795)
16. Pockros PJ, Shiffman ML, Schiff ER, et al. Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy. Hepatology. 2004;40:1450-1458. (Pubitemid 39657021)
17. Shiffman ML, Salvatore J, Hubbard S, et al. Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha. Hepatology. 2007;46:371-379. (Pubitemid 47344771)
18. Younossi ZM, Nader FH, Bai C, et al. A phase II dose finding study of darbepoetin alpha and filgrastim for the management of anaemia and neutropenia in chronic hepatitis C treatment. J Viral Hepat. 2008;15: 370-378. (Pubitemid 351473630)
19. Koirala J, Gandotra SD, Rao S, et al. Granulocyte colony-stimulating factor dosing in pegylated interferon alpha-induced neutropenia and its impact on outcome of anti-HCV therapy. J Viral Hepat. 2007;14: 782-787. (Pubitemid 47561582)
20. Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol. 1991;13:372-374.
21. Fredrick RT, Hassanein TI. Role of growth factors in the treatment of patients with HIV/HCV coinfection and patients with recurrent hepatitis C following liver transplantation. J Clin Gastroenterol. 2005;39: S14-S22. (Pubitemid 40024233)
22. Myers RP, Benhamou Y, Bochet M, et al. Pegylated interferon alpha 2b and ribavirin in HIV/hepatitis C virus-co-infected non-responders and relapsers to IFN-based therapy. AIDS. 2004;18:75-79. (Pubitemid 38402320)
23. Cargnel A, Angeli E, Mainini A, et al. Open, randomized, multicentre Italian trial on PEG-IFN plus ribavirin versus PEG-IFN monotherapy for chronic hepatitis C in HIV-coinfected patients on HAART. Antivir Ther. 2005;10:309-317. (Pubitemid 41151037)
24. Belperio PS, Rhew DC. Prevalence and outcomes of anemia in individuals with human immunodeficiency virus: a systematic review of the literature. Am J Med. 2004;116(suppl 7A):S27-S43.
25. Russmann S, Grattagliano I, Portincasa P, et al. Ribavirin-induced anemia: mechanisms, risk factors and related targets for future research. Curr Med Chem. 2006;13:3351-3357. (Pubitemid 44669779)
26. Grattagliano I, Russmann S, Palmieri VO, et al. Glutathione peroxidase, thioredoxin, and membrane protein changes in erythrocytes predict ribavirin-induced anemia. Clin Pharmacol Ther. 2005;78:422-432. (Pubitemid 41393677)
27. Larrat S, Stanke-Labesque F, Plages A, et al. Ribavirin quantification in combination treatment of chronic hepatitis C. Antimicrob Agents Chemother. 2003;47:124-129. (Pubitemid 36070352)
28. Jacobson IM, Brown RS, Jr., Freilich B, et al. Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial. Hepatology. 2007;46:971-981. (Pubitemid 350144761)
29. Jen JF, Glue P, Gupta S, et al. Population pharmacokinetic and pharmacodynamic analysis of ribavirin in patients with chronic hepatitis C. Ther Drug Monit. 2000;22:555-565.
30. Jaresko GS. Etiology of neutropenia in HIV-infected patients. Am J Health Syst Pharm. 1999;56(suppl 5):S5-S8. (Pubitemid 30020283)
31. Everson GT, Hoefs JC, Seeff LB, et al. Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: lessons from the HALT-C trial. Hepatology. 2006;44:1675-1684. (Pubitemid 44953672)
32. Dar Santos AE, Partovi N, Ford JA, et al. Use of hematopoietic growth factors as adjuvant therapy for anemia and neutropenia in the treatment of hepatitis C. Ann Pharmacother. 2007;41:268-275. (Pubitemid 46340057)
33. Bennett CL, Silver SM, Djulbegovic B, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA. 2008;299:914-924. (Pubitemid 351397066)
34. Hadland BK, Longmore GD. Erythroid-stimulating agents in cancer therapy: potential dangers and biologic mechanisms. J Clin Oncol. 2009;27: 4217-4226.
35. Del Rio RA, Post AB, Singer ME. Cost-effectiveness of hematologic growth factors for anemia occurring during hepatitis C combination therapy. Hepatology. 2006;44:1598-1606. (Pubitemid 44953665)
36. Muir AJ, McHutchison JG. Growth factors during HCV therapy may be "cost-effective", but are they "effective"? Hepatology. 2006;44: 1400-1403. (Pubitemid 44953644)
37. Sulkowski MS, Shiffman ML, Afdhal NH, et al. Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate. Gastroenterology. 2010;139:1602-1611.
38. Behler CM, Vittinghoff E, Lin F, et al. Hematologic toxicity associated with interferon-based hepatitis C therapy in HIV type 1-coinfected subjects. Clin Infect Dis. 2007;44:1375-1383. (Pubitemid 46717302)
39. Perez-Olmeda M, Nunez M, Romero M, et al. Pegylated IFN-alpha2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients. AIDS. 2003;17:1023-1028. (Pubitemid 36549714)